Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice

British Journal of Cancer

Volumn 73, Issue 10, 1996, Pages 1166-1170

  Kondo, A ^a   Maeta, M ^a   Oka, A ^a   Tsujitani, S ^a   Ikeguchi, M ^a   Kaibara, N ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Cisplatin; Fluid osmolarity; Intraperitoneal chemotherapy; Peritoneal carcinomatosis

Indexed keywords

CISPLATIN; HYPERTONIC SOLUTION; HYPOTONIC SOLUTION; ISOTONIC SOLUTION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; INTRAPERITONEAL DRUG ADMINISTRATION; LD 50; MALE; MOUSE; NONHUMAN; OSMOLARITY; PRIORITY JOURNAL; RAT;

EID: 0029999741     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.225     Document Type: Article

References (25)

1. AAMDAL S, FODSTAD Ø, KAALHUS O AND PHIL A. (1984). Reduced antineoplastic activity in mice of cisplatin administered with high salt concentration in the vehicle. J. Natl Cancer Inst., 73, 743-752.
2. BRASCH K, SELIGY VL AND SETTEERFIELD G. (1972). Effects of low salt concentration on structural organization and template activity of chromatin in chicken erythrocyte nuclei. Exp. Cell Res., 65, 61-72.
3. BUNGO M, FUJIWARA Y, KASAHARA K, NAKAGAWA K, OHE Y, SASAKI Y, IRONO S AND SAIJO N. (1990). Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum (II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res., 50, 2549-2553.
4. CAMPBELL AB, KALMAN SM AND JACOBS C. (1983). Plasma platinum levels relationship to cisplatin dose and nephrotoxicity. Cancer Treat. Rep., 67, 169-172.
5. CHIU S, FRIEDMAN LR, XUE L AND OLEINICK NL. (1986). Modification of DNA damage in transcriptionally active vs. bulk chromatin. J. Radiat. Oncol. Biol. Phys., 12, 1529-1532.
6. CUNLIFFE WJ AND SUGARBAKER PH. (1989). Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy. Br. J. Surg., 76, 1082-1090.
7. DALEY-YATES PT AND MCBRIEN DCH. (1984). Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin. Biochem. Pharmacol., 33, 3063-3070.
8. EASTMAN A. (1987). The formation, isolation, and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol. Ther., 34, 155-166.
9. FINNEY DJ. (1952). Graphical estimation of relative potency from quantal responses. J. Pharmacol. Exp. Therap., 104, 440-444.
10. GROOSE E, WALKER L AND MASTERS JR. (1986). The influence of osmolality on drug cytotoxicity in vitro. Br. J. Cancer, 54, 181.
11. KOCIBA RJ AND SLEIGHT SD. (1971). Acute toxicologic effects of cis-diamminedichloroplatinum (NSC-119875) in the male rat. Cancer Chemother. Rep. 55, 1-8.
12. KRAKER AJ AND MOORE CW. (1988). Accumulation of cis-diamminedichloroplatinum (II) and platinum analogs by platinum-resistant murine leukemia cells in vitro. Cancer Res., 48, 9-13.
13. LEROY AF, WEHLING ML, SPONSELLER HL, FRIAUF WS, SOLOMON RE, DEDRICK RL, LITTERST CL, GRAM TE, GUARINO AM AND BECKER DA. (1977). Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem. Med., 18, 184-191.
14. LITTERST CL. (1981). Alterations in the toxicity of cis-dichlorodiammineplatinum-II and in tissue localization. Toxicol. Appl. Pharmacol., 61, 99-108.
15. LOS G AND MCVIE JG. (1990). Experimental and clinical status of intraperitoneal chemotherapy. Eur. J. Cancer, 26, 755-762.
16. LOS G, MUTSAERS PHA, VAN DER VIJGH WJF, BALDEW GS, DE GRAAF PW AND MCVIE JG. (1989). Direct diffusion of cis-diamminedichloroplatinum (II) in intraperitoneal rat tumours after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res., 49, 3380-3384.
17. LOS G, VERDEGAAL E, NOTEBORN HPJM, RUEVEKAMP M, DEGRAEF A, MEESTERS EW, HUNINK TBD AND MCVIE JG. (1991). Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action. Biochem. Pharmacol., 42, 357-363.
18. LOWRY OH, ROSEBROUGH NJ, FALL AL AND RANDALL RJ. (1951). Protein measurement with the folin phenol reagent. J. Biol. Chem., 193, 265-275.
19. MANNEL RS, STRATTON JA, MORGAN G, RETTENMAIER MA, LIAO SY AND DISAIA P. (1989). Intraperitoneal cisplatin: comparison of antitumor activity and toxicity as a function of solvent saline concentration. Gynecol. Oncol., 34, 50-53.
20. MARKMAN M, REICHMAN B, HAKES T, CURTIN J, JONES W, LEWIS JR. JL, BARAKAT R, RUMIN S, MYCHALCZAK B, SAIGO P, ALMADRONES L AND HOSKINS W. (1993). Intraperitoneal chemotherapy in the management of ovarian cancer. Cancer, 71, 1565-1570.
21. ROSENBERG B. (1979). Anticancer activity of cis-dichlorodiammineplatinum (II) and some relevant chemistry. Cancer Treat. Rep., 63, 1433-1438.
22. SMITH E AND BROCK AP. (1989). The effect of reduced osmolarity on platinum drug toxicity. Br. J. Cancer, 59, 873-875.
23. STEPHEN RL, NOVAK JM, JENSEN EM, KABLITZ C AND BUYS SS. (1990). Effect of osmotic pressure on uptake of chemotherapeutic agents by carcinoma cells. Cancer Res., 50, 4704-4708.
24. TSUJITANI S, OKUYAMA T, WATANABE A, ABE Y, MAEHARA Y AND SUGIMACHI K. (1993). Intraperitoneal cisplatin during surgery for gastric cancer and peritoneal seeding. Anticancer Res., 13, 1831-1834.
25. WHITLAM JB AND BROWN KF. (1981). Ultrafiltration in serum protein binding determinations. J. Pharm. Sci., 70, 146-150.